Open AccessSilencing of syndecan-binding protein enhances the inhibitory effect of tamoxifen and increases cellular sensitivity to estrogen
Author(s) -
Jun Zhang,
Xiaolong Qian,
Fangfang Liu,
Xiaojing Guo,
Feng Gu,
Li Fu
Publication year - 2018
Publication title -
cancer biology and medicine
Language(s) - English
Resource type - Journals
ISSN - 2095-3941
DOI - 10.20892/j.issn.2095-3941.2017.0122
Subject(s) - tamoxifen , gene silencing , estrogen receptor , cell growth , estrogen , cell cycle , cancer research , mtt assay , antiestrogen , western blot , biology , cell , chemistry , endocrinology , medicine , cancer , breast cancer , biochemistry , gene
Tamoxifen is used as a complementary treatment for estrogen receptor (ER)-positive breast cancer (BCa), but many patients developed resistance. The aim of this study was to examine the role of syndecan-binding protein (SDCBP) silencing in ER-positive BCa cells.